Samsung Bioepis Co., Ltd., a leading biopharmaceutical company headquartered in South Korea (KR), is renowned for its innovative approach in the biosimilars industry. Founded in 2012, the company has rapidly established itself as a key player in the global market, focusing on the development and commercialisation of high-quality biosimilars and biologics. With a strong presence in major operational regions including North America, Europe, and Asia, Samsung Bioepis offers a diverse portfolio of products that includes biosimilars for oncology and autoimmune diseases. Their commitment to rigorous research and development, combined with advanced manufacturing capabilities, sets them apart in a competitive landscape. Notable achievements include strategic partnerships with global pharmaceutical leaders, enhancing their market position and expanding access to affordable treatments. Samsung Bioepis continues to drive innovation, making significant contributions to the healthcare sector.
How does Samsungbioepis Co,.Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Samsungbioepis Co,.Ltd's score of 39 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Samsungbioepis Co., Ltd. reported total carbon emissions of approximately 6,323,850 kg CO2e. This figure includes Scope 1 emissions of about 1,220,325 kg CO2e and Scope 2 emissions of approximately 5,103,525 kg CO2e. Additionally, the company disclosed significant Scope 3 emissions, with notable contributions from purchased goods and services (about 37,809,000 kg CO2e), business travel (approximately 1,416,000 kg CO2e), and employee commute (around 1,073,000 kg CO2e). Samsungbioepis has set ambitious climate commitments, aiming to reduce its greenhouse gas (GHG) emissions by 32% from a 2022 baseline by the year 2030. This target applies to both Scope 1 and Scope 2 emissions, reflecting a comprehensive approach to mitigating its carbon footprint. The emissions data for Samsungbioepis is cascaded from its parent company, Samsung Biologics Co., Ltd., which plays a significant role in shaping the sustainability initiatives of its subsidiaries. The company is actively working towards these reduction targets while maintaining transparency in its emissions reporting.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,433,412 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,296,110 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Samsungbioepis Co,.Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.